Primary hyperlipidaemia type IIa, IIb, III, IV and V; secondary hyperlipidaemia not responsive to other measures.
1200mg daily in 2 divided doses. Range 0.9 - 1.5g/day.
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
Decreases serum triglycerides and very low-density lipoprotein [VLDL] cholesterol and increases high-density lipoprotein [HDL].
Oestrogen therapy; monitor therapy [withdraw drug after 3 months if no adequate re- sponse]; perform periodic blood counts in the first 12 months of administration; if used with cholestyra- mine there should be 2 hours period between the two medicines.
Renal and hepatic impairment; pregnancy and lactation; primary biliary cirrhosis; gall bladder disease.
GI disorders; myotoxicity [with myas- thenia and myalgia]; hair loss; weight gain; anaemia; and leucopenia.